Control of virus-induced lymphoproliferation: Epstein-Barr virus- induced lymphoproliferation and host immunity

C. M. Rooney; C. A. Smith; H. E. Heslop

doi:10.1016/S1357-4310(96)10054-X

Control of virus-induced lymphoproliferation: Epstein-Barr virus- induced lymphoproliferation and host immunity

C. M. Rooney, C. A. Smith, H. E. Heslop

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

Epstein-Barr virus (EBV) is a latent herpesvirus that is associated with a number of tumors. EBV-infected cells show three patterns of latency ranging from type 1, where only one EBV-encoded antigen is expressed, to type 3, where all nine latent cycle proteins encoded by EBV are expressed. Malignancies exhibiting the type 3 latency pettern are highly immunogenic and occur only in immunocompromised patients. It has recently been shown that adoptive immunotherepy with EBV-specific cytotoxic T lymphocytes is an effective therapy for such tumors. Immunotherapy strategies and approaches to increase tumor immunogenicity are now being evaluated in tumors expressing type 2 latency.

Original language	English (US)
Pages (from-to)	24-30
Number of pages	7
Journal	Molecular Medicine Today
Volume	3
Issue number	1
DOIs	https://doi.org/10.1016/S1357-4310(96)10054-X
State	Published - 1997

ASJC Scopus subject areas

Molecular Medicine
Genetics

Access to Document

10.1016/S1357-4310(96)10054-X

Cite this

@article{e6834a08d02443e98314e769f635900a,

title = "Control of virus-induced lymphoproliferation: Epstein-Barr virus- induced lymphoproliferation and host immunity",

abstract = "Epstein-Barr virus (EBV) is a latent herpesvirus that is associated with a number of tumors. EBV-infected cells show three patterns of latency ranging from type 1, where only one EBV-encoded antigen is expressed, to type 3, where all nine latent cycle proteins encoded by EBV are expressed. Malignancies exhibiting the type 3 latency pettern are highly immunogenic and occur only in immunocompromised patients. It has recently been shown that adoptive immunotherepy with EBV-specific cytotoxic T lymphocytes is an effective therapy for such tumors. Immunotherapy strategies and approaches to increase tumor immunogenicity are now being evaluated in tumors expressing type 2 latency.",

author = "Rooney, \{C. M.\} and Smith, \{C. A.\} and Heslop, \{H. E.\}",

note = "Funding Information: Acknowledgements. {\textquoteleft}Ihis work was supported by NIH grants CA21684, CA21765 (CORE) HL 55703, the Assisi Foundation of Memphis and ALSAC (American Lebanese Syrian Associated Charities). We thank Sharon Namn for expert scientific editing.",

year = "1997",

doi = "10.1016/S1357-4310(96)10054-X",

language = "English (US)",

volume = "3",

pages = "24--30",

journal = "Molecular Medicine Today",

issn = "1357-4310",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Control of virus-induced lymphoproliferation

T2 - Epstein-Barr virus- induced lymphoproliferation and host immunity

AU - Rooney, C. M.

AU - Smith, C. A.

AU - Heslop, H. E.

N1 - Funding Information: Acknowledgements. ‘Ihis work was supported by NIH grants CA21684, CA21765 (CORE) HL 55703, the Assisi Foundation of Memphis and ALSAC (American Lebanese Syrian Associated Charities). We thank Sharon Namn for expert scientific editing.

PY - 1997

Y1 - 1997

N2 - Epstein-Barr virus (EBV) is a latent herpesvirus that is associated with a number of tumors. EBV-infected cells show three patterns of latency ranging from type 1, where only one EBV-encoded antigen is expressed, to type 3, where all nine latent cycle proteins encoded by EBV are expressed. Malignancies exhibiting the type 3 latency pettern are highly immunogenic and occur only in immunocompromised patients. It has recently been shown that adoptive immunotherepy with EBV-specific cytotoxic T lymphocytes is an effective therapy for such tumors. Immunotherapy strategies and approaches to increase tumor immunogenicity are now being evaluated in tumors expressing type 2 latency.

AB - Epstein-Barr virus (EBV) is a latent herpesvirus that is associated with a number of tumors. EBV-infected cells show three patterns of latency ranging from type 1, where only one EBV-encoded antigen is expressed, to type 3, where all nine latent cycle proteins encoded by EBV are expressed. Malignancies exhibiting the type 3 latency pettern are highly immunogenic and occur only in immunocompromised patients. It has recently been shown that adoptive immunotherepy with EBV-specific cytotoxic T lymphocytes is an effective therapy for such tumors. Immunotherapy strategies and approaches to increase tumor immunogenicity are now being evaluated in tumors expressing type 2 latency.

UR - https://www.scopus.com/pages/publications/0031426570

UR - https://www.scopus.com/inward/citedby.url?scp=0031426570&partnerID=8YFLogxK

U2 - 10.1016/S1357-4310(96)10054-X

DO - 10.1016/S1357-4310(96)10054-X

M3 - Review article

C2 - 9021739

AN - SCOPUS:0031426570

SN - 1357-4310

VL - 3

SP - 24

EP - 30

JO - Molecular Medicine Today

JF - Molecular Medicine Today

IS - 1

ER -

Control of virus-induced lymphoproliferation: Epstein-Barr virus- induced lymphoproliferation and host immunity

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this